MedTrace Logo

Effects of Astaxanthin Supplementation

NCT06511960 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-07-22

No results posted yet for this study

Summary

Astaxanthin is a potent antioxidant and anti-inflammatory carotenoid. Research examining whether astaxanthin (AX) could counteract exercise-induced muscle damage and improve exercise capacity reported inconsistent results.Therefore, the aim of this study was to explore the impact of 4 weeks supplementation with AX on muscle damage markers, total antioxidant status, and subjective marker of muscle pain. Twenty-four males were randomly assigned to the AX12 group (12 mg/day; n=8), AX36 group (36 mg/day; n=9), or placebo group (PLC; n=7). After 4 weeks of supplementation, blood samples were collected at rest, immediately after, and at 2, 24, 48, and 72 hours following eccentric arm exercise at 85% of predetermined one repetition maximum to assess muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.

Conditions

  • Dietary Supplements

Interventions

OTHER

Astaxanthin (12 mg/day) intervention

12 mg/day astaxanthin was administrated to all participants in the astaxanthin 12 mg/day groupfor 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.

OTHER

36 mg/day astaxanthin intervention

36 mg/day astaxanthin was administrated to all participants in the astaxanthin 36 mg/day group for 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.

OTHER

Placebo

12 mg/day placebo was administrated to all participants in the placebo group for 4 weeks. Following the placebo supplementation, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.

Sponsors & Collaborators

  • Hacettepe University

    lead OTHER

Principal Investigators

  • Muhammed Atakan, PhD · Hacettepe University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
25 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2024-01-01
Completion
2024-04-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06511960 on ClinicalTrials.gov